Have we made progress in the management of chronic graft-vs-host disease?

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 4, 2010, Pages 529-535

  Lee, Stephanie J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; Chronic graft vs host disease; Incidence; Quality of life; Survival

Indexed keywords

ALEFACEPT; ALEMTUZUMAB; AZATHIOPRINE; BORTEZOMIB; CLOFAZIMINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; ETANERCEPT; ETRETIN; HALOFUGINONE; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2; LIDOCAINE; METHOTREXATE; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PLACEBO; PRAVASTATIN; RAPAMYCIN; RITUXIMAB; THALIDOMIDE; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; PUVA; QUALITY OF LIFE; REVIEW;

CHRONIC DISEASE; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 78649911512     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2010.09.016     Document Type: Review

References (39)

1. S.J. Lee, and M.E. Flowers Recognizing and managing chronic graft-versus-host disease Hematology Am Soc Hematol Educ Program 2008 134 141
2. B.L. Stewart, B. Storer, J. Storek, H.J. Deeg, R. Storb, and J.A. Hansen Duration of immunosuppressive treatment for chronic graft-versus-host disease Blood 104 2004 3501 3506
3. C.J. Fraser, S. Bhatia, K. Ness, A. Carter, L. Francisco, and M. Arora Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the bone marrow transplant survivor study Blood 108 2006 2867 2873
4. S. Bhatia, L. Francisco, A. Carter, C.L. Sun, K.S. Baker, and J.G. Gurney Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the bone marrow transplant survivor study Blood 110 2007 3784 3792 (Pubitemid 350159650)
5. J.M. Goldman, N.S. Majhail, J.P. Klein, Z. Wang, K.A. Sobocinski, and M. Arora Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase J Clin Oncol 28 2010 1888 1895
6. H.J. Deeg, W. Leisenring, R. Storb, J. Nims, M.E. Flowers, and R.P. Witherspoon Long-term outcome after marrow transplantation for severe aplastic anemia Blood 91 1998 3637 3645
7. R. Storb, H.J. Deeg, M. Pepe, F. Appelbaum, C. Anasetti, and P. Beatty Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial Blood 73 1989 1729 1734 (Pubitemid 19131924)
8. M. Ross, G.M. Schmidt, J.C. Niland, M.D. Amylon, A.C. Dagis, and G.D. Long Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs-host disease: effect on chronic graft-vs-host disease and long-term survival Biol Blood Marrow Transplant 5 1999 285 291
9. A. Bacigalupo, M.T. Van Lint, D. Occhini, F. Gualandi, T. Lamparelli, and G. Sogno Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia Blood 77 1991 1423 1428
10. E. Kansu, T. Gooley, M.E. Flowers, C. Anasetti, H.J. Deeg, and R.A. Nash Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial Blood 98 2001 3868 3870
11. R. Storb, W. Leisenring, C. Anasetti, F.R. Appelbaum, H.J. Deeg, and K. Doney Methotrexate and cyclosporine for graft-vs-host disease prevention: what length of therapy with cyclosporine? Biol Blood Marrow Transplant 3 1997 194 201
12. K.M. Sullivan, J. Storek, K.J. Kopecky, J. Jocom, G. Longton, and M. Flowers A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery Biol Blood Marrow Transplant 2 1996 44 53
13. D.J. Winston, J.H. Antin, S.N. Wolff, B.E. Bierer, T. Small, and K.B. Miller A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation Bone Marrow Transplant 28 2001 187 196
14. S.Z. Pavletic, S.L. Carter, N.A. Kernan, J. Henslee-Downey, A.M. Mendizabal, and E. Papadopoulos Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation Blood 106 2005 3308 3313
15. T. Fong, K. Trinkaus, D. Adkins, R. Vij, S.M. Devine, and M. Tomasson A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation Biol Blood Marrow Transplant 13 2007 1201 1206
16. N.J. Chao, P.M. Parker, J.C. Niland, R.M. Wong, A. Dagis, and G.D. Long Paradoxical effect of thalidomide prophylaxis on chronic graft-vs-host disease Biol Blood Marrow Transplant 2 1996 86 92
17. A. Bacigalupo, T. Lamparelli, G. Barisione, P. Bruzzi, S. Guidi, and P.E. Alessandrino Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation Biol Blood Marrow Transplant 12 2006 560 565
18. J. Finke, W.A. Bethge, C. Schmoor, H.D. Ottinger, M. Stelljes, and A.R. Zander Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial Lancet Oncol 10 2009 855 864
19. J. Morton, C. Hutchins, and S. Durrant Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells Blood 98 2001 3186 3191
20. L. Luznik, J. Bolanos-Meade, M. Zahurak, A.R. Chen, B.D. Smith, and R. Brodsky High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease Blood 115 2010 3224 3230
21. L. Luznik, P.V. O'Donnell, H.J. Symons, A.R. Chen, M.S. Leffell, and M. Zahurak HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide Biol Blood Marrow Transplant 14 2008 641 650
22. A.H. Filipovich, D. Weisdorf, S. Pavletic, G. Socie, J.R. Wingard, and S.J. Lee National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report Biol Blood Marrow Transplant 11 2005 945 956 (Pubitemid 41754712)
23. H.M. Shulman, D. Kleiner, S.J. Lee, T. Morton, S.Z. Pavletic, and E. Farmer Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology working group report Biol Blood Marrow Transplant 12 2006 31 47
24. K.R. Schultz, D.B. Miklos, D. Fowler, K. Cooke, J. Shizuru, and E. Zorn Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report Biol Blood Marrow Transplant 12 2006 126 137
25. S.Z. Pavletic, P. Martin, S.J. Lee, S. Mitchell, D. Jacobsohn, and E.W. Cowen Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response criteria working group report Biol Blood Marrow Transplant 12 2006 252 266 (Pubitemid 43273710)
26. D. Couriel, P.A. Carpenter, C. Cutler, J. Bolanos-Meade, N.S. Treister, and J. Gea-Banacloche Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary therapy and supportive care working group report Biol Blood Marrow Transplant 12 2006 375 396 (Pubitemid 43380955)
27. P.J. Martin, D. Weisdorf, D. Przepiorka, S. Hirschfeld, A. Farrell, and J.D. Rizzo National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of clinical trials working group report Biol Blood Marrow Transplant 12 2006 491 505 (Pubitemid 43956368)
28. M. Jagasia, J. Giglia, W. Chinratanalab, S. Dixon, H. Chen, and H. Frangoul Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria Biol Blood Marrow Transplant 13 2007 1207 1215
29. M. Arora, S. Nagaraj, J. Witte, T.E. DeFor, M. MacMillan, and L.J. Burns New classification of chronic GVHD: added clarity from the consensus diagnoses Bone Marrow Transplant 43 2009 149 153
30. B.S. Cho, C.K. Min, K.S. Eom, Y.J. Kim, H.J. Kim, and S. Lee Feasibility of NIH consensus criteria for chronic graft-versus-host disease Leukemia 23 2009 78 84
31. A.C. Vigorito, P.V. Campregher, B.E. Storer, P.A. Carpenter, C.K. Moravec, and H.P. Kiem Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD Blood 114 2009 702 708
32. K.M. Sullivan, H.M. Shulman, R. Storb, P.L. Weiden, R.P. Witherspoon, and G.B. McDonald Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression Blood 57 1981 267 276
33. K.M. Sullivan, R.P. Witherspoon, R. Storb, P. Weiden, N. Flournoy, and S. Dahlberg Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation Blood 72 1988 546 554
34. K.M. Sullivan, R.P. Witherspoon, R. Storb, H.J. Deeg, S. Dahlberg, and J.E. Sanders Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease Blood 72 1988 555 561
35. M. Arora, J.E. Wagner, S.M. Davies, B.R. Blazar, T. DeFor, and H. Enright Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease Biol Blood Marrow Transplant 7 2001 265 273
36. S. Koc, W. Leisenring, M.E. Flowers, C. Anasetti, H.J. Deeg, and R.A. Nash Thalidomide for treatment of patients with chronic graft-versus-host disease Blood 96 2000 3995 3996
37. S. Koc, W. Leisenring, M.E. Flowers, C. Anasetti, H.J. Deeg, and R.A. Nash Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone Blood 100 2002 48 51
38. A.L. Gilman, K.W. Chan, A. Mogul, C. Morris, F.D. Goldman, and M. Boyer Hydroxychloroquine for the treatment of chronic graft-versus-host disease Biol Blood Marrow Transplant 6 2000 327 334
39. P.J. Martin, B.E. Storer, S.D. Rowley, M.E. Flowers, S.J. Lee, and P.A. Carpenter Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease Blood 113 2009 5074 5082